Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Frontiers in Pharmacology|May 16, 2013
Systemic cancer therapy: achievements and challenges that lie aheadMichael O Palumbo, Petr Kavan, Wilson H Miller, et al.
Clinical Chemistry|July 22, 2016
Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular LymphomaMiguel Alcaide, Stephen Yu, Kevin Bushell, et al.
Blood|May 13, 2009
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirinSarit Assouline, Biljana Culjkovic, Eftihia Cocolakis, et al.
Vaccine|February 2, 2022
B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disordersMégane Tanguay, Marianne Boutin, Annemarie Laumaea, et al.
Leukemia & Lymphoma|April 21, 2011
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?Lisa M Lima, Keeran Sampat, Sarit Assouline, et al.
Critical Reviews in Oncology/Hematology|May 7, 2010
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot studyMartine T E Puts, Johanne Monette, Veronique Girre, et al.
Elife|November 8, 2017
The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activityHiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, Audrey Emond, et al.
Leukemia & Lymphoma|February 18, 2011
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)C Tom Kouroukis, Louis A V Fernandez, Michael Crump, et al.
Scientific Reports|January 18, 2022
Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphomaAlexandre Benoit, Elisabeth Bou-Petit, Hsiang Chou, et al.
British Journal of Haematology|September 6, 2018
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphomaDavid J Andorsky, Kathryn S Kolibaba, Sarit Assouline, et al.
Pageof 9